LAVATELLI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 1.625
EU - Europa 1.145
AS - Asia 720
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 3.496
Nazione #
US - Stati Uniti d'America 1.619
CN - Cina 668
IE - Irlanda 532
FI - Finlandia 190
DE - Germania 131
UA - Ucraina 113
IT - Italia 83
SE - Svezia 30
GB - Regno Unito 18
JP - Giappone 18
FR - Francia 16
IN - India 14
BE - Belgio 8
CA - Canada 6
SG - Singapore 6
AT - Austria 5
HU - Ungheria 4
IR - Iran 4
NL - Olanda 4
TR - Turchia 4
AU - Australia 2
EE - Estonia 2
ES - Italia 2
EU - Europa 2
KR - Corea 2
RS - Serbia 2
RU - Federazione Russa 2
TH - Thailandia 2
CH - Svizzera 1
HK - Hong Kong 1
LV - Lettonia 1
MU - Mauritius 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 3.496
Città #
Dublin 532
Chandler 418
Jacksonville 184
Nanjing 171
Ashburn 143
Helsinki 100
Beijing 95
Nanchang 80
Princeton 78
Lawrence 75
Wilmington 70
Medford 69
Hebei 54
Shenyang 51
Jiaxing 43
Changsha 39
Ann Arbor 38
Shanghai 38
Hangzhou 34
Pavia 30
Tianjin 24
Boardman 20
New York 20
Norwalk 20
Woodbridge 18
Piscataway 16
Tokyo 15
Milan 10
Brussels 8
Fairfield 8
Los Angeles 8
Seattle 8
Washington 8
Verona 7
Chandigarh 6
Redwood City 5
Singapore 5
Tamm 5
Budapest 4
Dearborn 4
Des Moines 4
Formia 4
Jinan 4
Kunming 4
Ningbo 4
Pune 4
San Francisco 4
Taizhou 4
Auburn Hills 3
Boston 3
Falkenstein 3
Rome 3
Toyama 3
Trino 3
Ban Kho 2
Bari 2
Belgrade 2
Berlin 2
Brunswick 2
Cardito 2
Deiva Marina 2
Feldthurns 2
Latisana 2
Limoges 2
Mountain View 2
Nieuwegein 2
Tappahannock 2
Victoria 2
Vienna 2
Vinovo 2
West Jordan 2
Zhengzhou 2
Ankara 1
Ardabil 1
Baltimore 1
Bolu 1
Borås 1
Cambridge 1
Campobasso 1
Cap-Sante 1
Cervera del Rio Alhama 1
Changchun 1
Delhi 1
East York 1
Fremont 1
Fuzhou 1
Genoa 1
Haikou 1
Indianapolis 1
Istanbul 1
Kemerovo 1
Kuala Lumpur 1
London 1
Lugano 1
Markham 1
Melbourne 1
Nagold 1
Prineville 1
Richmond 1
Rockville 1
Totale 2.675
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 100
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 82
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 76
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 75
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 75
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 68
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 66
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 66
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 65
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 64
Biochemical markers in early diagnosis and management of systemic amyloidoses 62
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 62
IceTrack: a biobank information management system maximizing flexibility and usability 62
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 60
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 58
AMICA: an electronic patient record specifically designed for an amyloidosis network. 58
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 57
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 57
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 56
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 56
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 56
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 56
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 54
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 54
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 54
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 54
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 52
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 51
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 51
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 51
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 51
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 49
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 49
Clinical proteomics for diagnosis and typing of systemic amyloidoses 49
Prognostication of survival and progression to dialysis in AA amyloidosis 48
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis 47
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 47
Regulated expression of amyloidogenic immunoglobulin light chains in mice 46
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 46
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 45
Changes in tissue proteome associated with ATTR amyloidosis: Insights into pathogenesis 44
A workflow management system for the biological samples exchange within the amyloidosis network 44
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 44
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 41
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 40
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 40
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 38
Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains 38
Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits 37
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 36
null 35
A practical approach to the diagnosis of systemic amyloidoses 35
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). 34
Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. 32
Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations 32
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 32
Age-related amyloidosis outside the brain: A state-of-the-art review 32
Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations 30
null 28
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 28
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 28
Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms 28
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 27
Proteomics in protein misfolding diseases. 27
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity 27
Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing 27
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 23
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 23
The workings of the amyloid diseases. 23
The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis 23
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 22
Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis 22
Clinical amyloid typing by proteomics: Performance evaluation and data sharing between two centres 22
Dissecting the molecular features of systemic light chain (Al) amyloidosis: Contributions from proteomics 22
Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration 21
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 21
A case of monoclonal gammopathy of renal significance 21
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 20
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 20
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 20
How do we improve treatments for patients with amyloidosis using proteomics? 16
Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders 15
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 14
Truncation of the constant domain drives amyloid formation by immunoglobulin light chains 13
Systemic amyloidoses and proteomics: The state of the art 13
Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis 13
Human wild-type and D76N β2-microglobulin variants are significant proteotoxic and metabolic stressors for transgenic C. elegans 11
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres 10
null 6
Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans 2
Totale 3.635
Categoria #
all - tutte 14.986
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.986


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20195 0 0 0 0 0 0 0 0 0 0 0 5
2019/2020740 210 304 0 22 3 24 3 27 2 88 36 21
2020/2021268 28 20 7 25 2 29 7 59 22 37 28 4
2021/2022301 2 5 2 4 6 2 6 39 20 3 36 176
2022/20231.365 177 112 18 76 114 118 10 56 605 8 31 40
2023/2024568 69 108 32 25 45 122 20 42 9 24 42 30
Totale 3.635